Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel.
about
Simvastatin improves the sexual health-related quality of life in men aged 40 years and over with erectile dysfunction: additional data from the erectile dysfunction and statin trialCardiovascular drug use and the incidence of erectile dysfunction.Association between renal function, erectile function and coronary artery disease: detection with coronary angiographyChanges in erectile dysfunction over time in relation to Framingham cardiovascular risk in the Boston Area Community Health (BACH) Survey.Is erectile dysfunction a reliable indicator of general health status in men?Heart Rate Variability: A Risk Factor for Female Sexual Dysfunction.The Association of Erectile Dysfunction and Cardiovascular Disease: A Systematic Critical Review.Does vitamin D deficiency contribute to erectile dysfunction?Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children's Oncology Group.Erectile dysfunction as an early sign of cardiovascular disease.Sexual dysfunction in the elderly: age or disease?The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease.The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.Beyond the lower urinary tract: the association of urologic and sexual symptoms with common illnesses.Vardenafil demonstrates first-dose success and reliability of penetration and maintenance of erection in men with erectile dysfunction - RELY-II.Erectile dysfunction as a harbinger for increased cardiometabolic risk.Stem and endothelial progenitor cells in erection biology.Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.Assessment of endothelial function in the patient with erectile dysfunction: an opportunity for the urologist.New horizons in erectile and endothelial dysfunction research and therapies.Hypogonadism in men with erectile dysfunction may be related to a host of chronic illnesses.Emerging role for TNF-α in erectile dysfunction.Gender-based cardiometabolic risk evaluation in minority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk.Assessment of EndoPAT scores in men with vasculogenic and non-vasculogenic erectile dysfunction.Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.Physical activity on endothelial and erectile dysfunction: a literature review.Erectile dysfunction as a predictor of early stage of coronary artery disease.Can simvastatin improve erectile function and health-related quality of life in men aged ≥40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971].Can simvastatin improve erectile function and health-related quality of life in men aged >40 years with erectile dysfunction? Rationale and design of the Erectile Dysfunction and Statins (EDS) Trial [ISRCTN66772971](1).Risk factors for erectile dysfunction in patients with cardiovascular disease.Hemodynamic effect of avanafil and glyceryl trinitrate coadministration.Associations of Self-Reported Erectile Function with Non-Invasive Measurements of Endothelial Function: A Preliminary Study.Occurrence of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome in patients with abdominal obesity. Where is a sufficient level of testosterone?Herpes simplex virus infection and erectile dysfunction: a nationwide population-based study.Sildenafil citrate efficacy 8 h postdose in men with mild to moderate erectile dysfunction.The impact of frequently encountered cardiovascular risk factors on sexual dysfunction in rheumatic disorders.Significance of platelet distribution width as a severity marker of erectile dysfunction.Assessment of the relationship between coronary artery ectasia and erectile function score.Cardiometabolic risk factors in patients with erectile dysfunction.Correlation Analysis of Erectile Dysfunction with Lower Urinary Tract Symptoms (LUTS) Degree and Clinical Features in LUTS Patients.
P2860
Q30769745-AA762A95-2A74-40F6-A133-793A73E66176Q34569844-97297122-29A7-4440-B075-78424A201EA5Q34962528-E19D330A-0E46-4367-A1D6-C67DA39DE287Q35007546-574CC6F4-A979-448A-8E04-79607254BDEEQ35643349-608F564F-14E5-47C7-B5AF-EC56902D3517Q35665299-5623502F-196F-4BEE-98C2-8076C5A24530Q35914768-56FB59FB-BCF5-4B04-8D6B-408C7D0773DAQ36187592-BA552B26-28EF-4DD0-A0AF-C3B75D78915CQ36222944-2B82E753-F4E7-45B9-AC15-2F3E334AC11DQ36359841-38543A37-3B13-4D86-B60A-1618A28721D7Q36359858-07A284A9-A174-493E-93CD-67659B88F266Q36399555-28AF0774-0C67-41AC-B9FB-C4E28136F593Q36500200-8999A656-A848-43E7-B999-A35C964D16A4Q36676598-03D5CD39-9F41-448B-A928-53FA6F33E62DQ36808439-CE27EB94-7135-4B78-BEC8-372617FB9CAEQ37058764-36F20166-96BF-4E87-8B44-3EBED285D1D6Q37078842-08C477DD-CA36-49A8-9A7A-D722C6B1C399Q37148383-683FC087-0A6D-4136-96B3-9D4397B49CA8Q37157274-02865C30-2E48-4906-90BA-1AB54E1B3B91Q37323289-28DAB00A-A531-445B-A840-4B15B0CB8A1BQ37607090-B55D1988-3F5A-4A17-B339-7725F1FEBC6EQ37719686-13A9D9B3-138C-4F86-B398-826A0E368C8FQ37825592-84DC8ECB-AC7C-400D-8F47-1CF4EE8FB54EQ38067490-6CE08A7A-4AE7-4245-9B23-6C859BF90FE8Q38126803-4E3022F5-0B4D-448F-A22C-2325555C04B0Q38217424-73EB32AA-F394-4DCE-A32D-6A87A816B470Q39370599-27C8916E-E98F-4555-A4AE-0D3A889E021BQ39604956-CF824169-F354-4ACE-9229-D68FCB987D3BQ39775989-517D91AD-6677-44CF-88C7-548CC0AFE5B5Q40862954-9BB96FA6-C35F-4727-9E9B-FE909E93CD21Q41859015-B28B7B5C-E010-4E09-9938-CCD4E0B8DC59Q43093621-377A2C6D-2B05-4936-AF2E-EB4DD0399561Q44790679-A111631D-CFB3-4FEF-BA66-25281D6B5853Q45352586-034B0F54-FEEE-4C40-8251-2882C3D5D750Q46558226-A090EBB2-F8A9-47C3-B661-0CCA0CF5354DQ51244876-8353B67A-04EF-440B-A40C-1D476DB5A397Q53042790-AA43BA94-6F53-489A-AB89-145FFEFAB247Q53154505-7AE471DB-23DF-4273-BED4-2501A1322B34Q55119520-D0619102-B47D-44CE-8432-FE3D4C7CA5DBQ55317597-5F68F3C7-98F1-4543-9FEA-BE5CD7A1049A
P2860
Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Erectile dysfunction is a mark ...... stitute expert advisory panel.
@ast
Erectile dysfunction is a mark ...... stitute expert advisory panel.
@en
type
label
Erectile dysfunction is a mark ...... stitute expert advisory panel.
@ast
Erectile dysfunction is a mark ...... stitute expert advisory panel.
@en
prefLabel
Erectile dysfunction is a mark ...... stitute expert advisory panel.
@ast
Erectile dysfunction is a mark ...... stitute expert advisory panel.
@en
P2093
P1476
Erectile dysfunction is a mark ...... stitute expert advisory panel.
@en
P2093
Alan J Bank
Harin Padma-Nathan
Kevin L Billups
Richard Williams
Stuart Katz
P304
40-50; discussion 50-2
P356
10.1111/J.1743-6109.2005.20104_1.X
P577
2005-01-01T00:00:00Z